Cita: January — Success in its pilot proteomics study of pancreatic cancer leads Celera to initiate studies in lung and colon cancer.
Cita: Sept - Dec — The Celera Diagnostics joint venture presents selected genetic association study data in four disease areas including risk for myocardial infarction, interferon responsiveness in patients infected with the hepatitis C virus, Alzheimer's disease and risk of metastasis in patients with breast cancer. Further studies are underway that may lead to new diagnostic products
Cita: October — Several preclinical Factor VIIa inhibitors pass pharmacokinetic screening and are being evaluated as anticoagulants. Other leading small molecule programs include histone deactylase (HDAC) inhibitors for cancer and tryptase inhibitors for asthma.
Además de asombrar los estudios que están haciendo, es la rapidez con que comienzan un nuevo estudio... con razón manejan tanto presupuesto.